S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Humana Stock Price, Forecast & Analysis (NYSE:HUM)

$318.90
-1.39 (-0.43 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$318.09
Now: $318.90
$321.48
50-Day Range
$250.62
MA: $279.92
$319.66
52-Week Range
$225.65
Now: $318.90
$336.13
Volume618,059 shs
Average Volume1.22 million shs
Market Capitalization$42.23 billion
P/E Ratio21.92
Dividend Yield0.69%
Beta0.85
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. Read More…

Industry, Sector and Symbol

Industry Hospital & medical service plans
Sub-IndustryManaged Health Care
SectorMedical
CUSIP44485910
Phone502-580-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$56.91 billion
Cash Flow$18.87 per share
Book Value$74.95 per share

Profitability

Net Income$1.68 billion

Miscellaneous

Employees41,600
Market Cap$42.23 billion
Next Earnings Date2/5/2020 (Estimated)
OptionableOptionable

Receive HUM News and Ratings via Email

Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.


Humana (NYSE:HUM) Frequently Asked Questions

What is Humana's stock symbol?

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

How often does Humana pay dividends? What is the dividend yield for Humana?

Humana announced a quarterly dividend on Thursday, October 24th. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.55 per share on Friday, January 31st. This represents a $2.20 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date of this dividend is Monday, December 30th. View Humana's Dividend History.

How will Humana's stock buyback program work?

Humana declared that its Board of Directors has authorized a stock buyback program on Friday, December 15th 2017, which permits the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its stock is undervalued.

How were Humana's earnings last quarter?

Humana Inc (NYSE:HUM) issued its quarterly earnings results on Wednesday, November, 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $4.58 by $0.45. The insurance provider had revenue of $16.24 billion for the quarter, compared to the consensus estimate of $16.15 billion. Humana had a return on equity of 22.32% and a net margin of 4.06%. The company's revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm earned $4.58 earnings per share. View Humana's Earnings History.

When is Humana's next earnings date?

Humana is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Humana.

What guidance has Humana issued on next quarter's earnings?

Humana issued an update on its FY19 earnings guidance on Wednesday, November, 6th. The company provided EPS guidance of $17.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $17.63.

What price target have analysts set for HUM?

17 brokers have issued 12 month price objectives for Humana's stock. Their forecasts range from $275.02 to $350.00. On average, they anticipate Humana's share price to reach $324.00 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for Humana.

What is the consensus analysts' recommendation for Humana?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana.

What are Wall Street analysts saying about Humana stock?

Here are some recent quotes from research analysts about Humana stock:
  • 1. According to Zacks Investment Research, "Humana’s shares have lost year-to-date against its industry’s gain. Moreover, the company has witnessed its 2020 earnings estimates move south over the last 30 days. Its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects high benefit expenses which will lead to an overall increase in operating expenses going forward. Also, increase in leverage might lead to heightened financial risk for the company and burden on margins. Nevertheless, it is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters." (4/11/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on HUM shares and maintain our 12-month price target of $325. After the market close on the company reaffirmed its 2018 EPS guidance. The company also provided updated 2019 membership metrics. Given the update, we are increasing our 2019 revenue and EPS estimates. The company had previously indicated that it expected 2019 adjusted EPS to grow above its stated long-term goal of 11-15%. With its filing on Wednesday, the company did not comment on 2019 EPS guidance, but will provide detailed 2019 financial guidance when it reports 4Q18 and year-end 2018 results on Wednesday, February 6, 2019." (1/2/2019)

Has Humana been receiving favorable news coverage?

News stories about HUM stock have been trending very negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Humana earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave media headlines about the insurance provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Humana.

Are investors shorting Humana?

Humana saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,920,000 shares, a decline of 16.2% from the September 30th total of 2,290,000 shares. Based on an average daily volume of 1,050,000 shares, the short-interest ratio is currently 1.8 days. Approximately 1.4% of the company's stock are short sold. View Humana's Current Options Chain.

Who are some of Humana's key competitors?

What other stocks do shareholders of Humana own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), Boeing (BA), Visa (V), Walt Disney (DIS), Mastercard (MA), NVIDIA (NVDA), Alibaba Group (BABA), JPMorgan Chase & Co. (JPM), Amgen (AMGN) and Micron Technology (MU).

Who are Humana's key executives?

Humana's management team includes the folowing people:
  • Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)
  • Mr. Brian Andrew Kane, Chief Financial Officer (Age 46)
  • Mr. Timothy S. Huval, Chief HR Officer (Age 53)
  • Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)
  • Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Healthcare Services (Age 51)

Who are Humana's major shareholders?

Humana's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Newport Trust Co (1.26%), California Public Employees Retirement System (0.63%), Diamond Hill Capital Management Inc. (0.55%), Sumitomo Mitsui Trust Holdings Inc. (0.40%), Calamos Advisors LLC (0.25%) and Unigestion Holding SA (0.23%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana.

Which institutional investors are selling Humana stock?

HUM stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Rhenman & Partners Asset Management AB, Scout Investments Inc., Newport Trust Co, Carillon Tower Advisers Inc., Coronation Fund Managers Ltd., Sector Gamma AS and Calamos Advisors LLC. Company insiders that have sold Humana company stock in the last year include Brian P Leclaire, Christopher H Hunter, David A Jr/Ky Jones, Heidi S Margulis and Roy A Beveridge. View Insider Buying and Selling for Humana.

Which institutional investors are buying Humana stock?

HUM stock was bought by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., Ardevora Asset Management LLP, Artemis Investment Management LLP, Vantage Investment Partners LLC, California Public Employees Retirement System, Railway Pension Investments Ltd, Zweig DiMenna Associates LLC and Rhumbline Advisers. View Insider Buying and Selling for Humana.

How do I buy shares of Humana?

Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Humana's stock price today?

One share of HUM stock can currently be purchased for approximately $318.90.

How big of a company is Humana?

Humana has a market capitalization of $42.23 billion and generates $56.91 billion in revenue each year. The insurance provider earns $1.68 billion in net income (profit) each year or $14.55 on an earnings per share basis. Humana employs 41,600 workers across the globe.View Additional Information About Humana.

What is Humana's official website?

The official website for Humana is http://www.humana.com/.

How can I contact Humana?

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected]


MarketBeat Community Rating for Humana (NYSE HUM)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  746 (Vote Outperform)
Underperform Votes:  792 (Vote Underperform)
Total Votes:  1,538
MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel